Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world’s leading pharmaceutical companies, including AstraZeneca, Eli Lilly and Company, Pfizer Inc., and Merck Research Laboratories. Most recently, Dr. Brenner served as the CSO at Pfenex Inc., which, using its patented Pfenex Expression Technology® platform, created an advanced pipeline of therapeutic equivalents, vaccines, biologics, and biosimilars. Pfenex was acquired by Ligand Pharmaceuticals Incorporated for approximately $516 million in October 2020.
Previously, Dr. Brenner served as the CSO at Recursion Pharmaceuticals, Inc., a company focused on accelerating drug discovery for rare diseases and diseases with high unmet medical need. Prior to his time at Recursion, he was Vice President and Head of Research & Early Development at Stoke Therapeutics, Inc., a biotechnology company using antisense oligonucleotides to increase gene expression for the treatment of rare diseases. Prior to Stoke, he was Executive Director at Merck, where he built a biotech unit from scratch, focusing his team’s research on diabetes and nonalcoholic steatohepatitis (NASH). Earlier in his career, Dr. Brenner was the Senior Director and Head of cardiovascular, renal, and metabolism (CVRM) biosciences at AstraZeneca. In addition, Dr. Brenner was an Associate Research Fellow at Pfizer where he led the islet biology and in vivo pharmacology in the CVMED Target Exploration Unit before assuming the role of Head of the Insulin Resistance Group.
What is Martin Brenner's net worth?
The estimated net worth of Martin Brenner is at least $39.39 thousand as of March 19th, 2026. Brenner owns 30,652 shares of iBio stock worth more than $39,388 as of September 18th. This net worth estimate does not reflect any other investments that Brenner may own. Learn More about Martin Brenner's net worth.
How do I contact Martin Brenner?
Has Martin Brenner been buying or selling shares of iBio?
Martin Brenner has not been actively trading shares of iBio in the last ninety days. Most recently, on Thursday, March 19th, Martin Brenner bought 12,336 shares of iBio stock. The stock was acquired at an average cost of $2.02 per share, with a total value of $24,918.72. Following the completion of the transaction, the insider now directly owns 30,652 shares of the company's stock, valued at $61,917.04. Learn More on Martin Brenner's trading history.
Who are iBio's active insiders?
Are insiders buying or selling shares of iBio?
In the last twelve months, iBio insiders bought shares 2 times. They purchased a total of 37,171 shares worth more than $75,085.42. The most recent insider tranaction occured on March, 19th when CFO
Felipe Duran bought 24,835 shares worth more than $50,166.70. Insiders at iBio own 1.6% of the company.
Learn More about insider trades at iBio. Information on this page was last updated on 3/19/2026.
